SCHEMBL3246448

SCHEMBL3246448

COc1ccc(S(=O)(=O)N(CCNCCN(C)C)c2ccc(Cl)cc2Cc2c(F)cccc2F)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.46
HCRTR2 O43614 3/20 0.43
HCRTR1 O43613 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 4/20 0.40
TSHR P16473 3/20 0.40
TP53 P04637 2/20 0.39
MCOLN3 Q8TDD5 2/20 0.39
POLB P06746 1/20 0.39
ALDH1A1 P00352 3/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
LMNA P02545 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PTGER1 P34995 1/20 0.36
CNR1 P21554 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3251551 0.92 HCRTR2 (0.49) PKMHCRTR2HCRTR1MAPTTSHR
SCHEMBL4870970 0.91 PKM (0.48) PKMHCRTR2HCRTR1SMN1; SMN2MAPT
SCHEMBL3257094 0.91 PKM (0.46) PKMHCRTR2HCRTR1MAPTTSHR
SCHEMBL3247333 0.89 PKM (0.46) PKMHCRTR2HCRTR1SMN1; SMN2MAPT
SCHEMBL3256037 0.88 PKM (0.48) PKMHCRTR2HCRTR1SMN1; SMN2MAPT
SCHEMBL3255886 0.88 PKM (0.48) PKMHCRTR2HCRTR1MAPTTSHR
SCHEMBL3255521 0.88 PKM (0.48) PKMHCRTR2HCRTR1MAPTTSHR
SCHEMBL3250401 0.87 PKM (0.49) PKMHCRTR2HCRTR1SMN1; SMN2MAPT
SCHEMBL3247054 0.87 PKM (0.49) PKMHCRTR2HCRTR1SMN1; SMN2MAPT
SCHEMBL4871023 0.87 PKM (0.52) PKMHCRTR2HCRTR1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 PKM 2524/4885HCRTR2 1/4885HCRTR1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.